表紙
市場調查報告書

3D細胞培養全球市場 - 成長,趨勢,預測(2019年∼2024年)

3D Cell Culture Market - Growth, Trends And Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 391456
出版日期 內容資訊 英文 116 Pages
商品交期: 2-3個工作天內
價格
3D細胞培養全球市場 - 成長,趨勢,預測(2019年∼2024年) 3D Cell Culture Market - Growth, Trends And Forecast (2020 - 2025)
出版日期: 2020年03月01日內容資訊: 英文 116 Pages
簡介

3D細胞培養市場,由於生命科學企業對研究開發的巨額投資,自動化大規模細胞培養系統的開發,及器官移植的必要性高漲等,而穩定成長。經驗豐富熟練的專家不足,及中小規模的研究所的預算限制,成為抑制市場成長的要素。

本報告提供全球3D細胞培養市場調查,市場概要,各技術、用途、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素及阻礙因素概要
  • 市場成長要素
    • 生命科學企業的巨大R&D投資
    • 自動大規模細胞培養系統的開發
    • 器官移植的需求高漲
    • 使用3D細胞培養模式作為體內實驗的替代法
    • 再生醫療的興趣高漲
  • 市場阻礙因素
    • 經驗豐富熟練的專家不足
    • 對中小規模的研究所的預算的限制
    • 3D細胞培養產品的一貫性的缺乏
    • 對高度的處理必要的嚴格的流程管理
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各技術
    • 細胞外矩陣(支架)
    • 生物反應器
    • 凝膠
    • 無支架平台
    • 微晶片
    • 其他
  • 各用途
    • 研究
    • 藥物研發
    • 人組織工程
    • 臨床
    • 幹細胞生物學
    • 其他
  • 各終端用戶
    • 研究所
    • 製藥、生物科技企業
    • 醫院、診斷中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • 3D Biotek LLC
    • Becton Dickinson and Company
    • Sigma Aldrich Corporation
    • Corning Incorporated
    • Thermo Fisher Scientific
    • Global Cell Solutions Inc.
    • Nanofiber Solutions Incorporation
    • Insphero AG
    • Lonza Group
    • Nano 3D Biosciences

第7章 市場機會與未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54434

The 3D cell culture market is witnessing a stable growth due to the factors, like use of 3D cell culture models as alternative tools for in vivo testing, development of automated large-scale cell culture systems, and rising need for organ transplantation. The 2D monolayer cell cultures were employed in cell-based screening and were considered as an effective means to discover new drug candidates. However, 2D cell cultures have limitations, like the loss of tissue-specific architecture, mechanical and biochemical cues, and cell-to-cell and cell-to-matrix interactions, thereby making them relatively poor models to predict drug responses for certain diseases. The 3D cell culture and co-culture models are advantageous, in that they not only enable drug safety and efficacy assessment in a more in vivo-like context than traditional 2D cell cultures, but they also eliminate the species differences that pose limitations in the interpretation of the preclinical outcomes, by allowing drug testing directly in human systems. A 3D cell culture is preferred to 2D cell culture, since it allows cells to grow in all directions in vitro, similar to how they would in vivo. Due to advantages of 3D cell culture over alternative tools, the adoption has benefited the researchers and drug developers. Hence, owing to these factors, the market is expected to witness rapid growth over the forecast period.

Key Market Trends

Drug Discovery Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period

Based on Application, the market is segmented into Drug Discovery, Tissue Engineering, Clinical Applications, and Other Applications. Conventionally, drug discovery has been carried out using animal models. However, with the explosion of drug molecules synthesized/discovered in the past two decades, there has been a growth in high-throughput screening. Consequently, drug discovery has become a process that was time-resource intensive. Additionally, animal testing is subject to ethical controversies. Hence, the rising demand for alternative methods for drug testing and drug discovery processes has gained momentum.

A specific application of 3D cell culture in drug discovery is organ-on-chips. These systems are being extensively employed by cancer therapeutic manufacturers for improving the benefit-risk balance by targeting precisely a particular cell type, a defined biomechanism, or a precise receptor. The current up-trend in cancer therapeutics' research is likely to further spur the application of 3D cell cultures in drug discovery. Over the forecast period, many novel cancer therapeutics are expected to receive market approval, which are likely to, in turn, drive the growth of the 3D cell culture market.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall 3D cell culture market with the United States accounting as the major contributor to the market. The United States is focusing more on R&D and is currently spending a lot on it. This has resulted in increasing technological advancements in the country. Many American applicants feature among the main patent applicants for the 3D cell culture domain. American applicants tend to develop their technologies in the United States, as well as in Asia. In 2016, an international collaboration between the United States, the United Kingdom, and the Netherlands, cancer-research heavy-weights, aimed to grow 1,000 new cell lines for scientists to study. The project is also expected to use cutting-edge techniques to generate its models, which will include 3D cultures called organoids, and cells that have been reprogrammed to grow indefinitely in culture. ICTDCCS 2018, 20th International Conference on 3D Cell Culture Systems, was held in Boston (the United States) on April 23-24, 2018. These factors have augmented the US 3D cell culture market and it is expected to further increase in the future.

Competitive Landscape

The 3D cell culture market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Corning Incorporated, Lonza AG, Merck KGaA, Thermo Fisher Scientific, etc., is increasing the overall competitive rivalry in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Use of 3D Cell Culture Models as Alternative Tools for In Vivo Testing
    • 4.2.2 Development of Automated Large-scale Cell Culture Systems
    • 4.2.3 Rising Need for Organ Transplantation
  • 4.3 Market Restraints
    • 4.3.1 Lack of Experienced and Skilled Professionals
    • 4.3.2 Budget Restriction for Small- and Medium-sized Laboratories
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Scaffold-Based 3D Cell Cultures
      • 5.1.1.1 Hydrogels/ECM Analogs
      • 5.1.1.2 Others
    • 5.1.2 Scaffold-Free 3D Cell Cultures
      • 5.1.2.1 3D Bioreactors
      • 5.1.2.2 Others
    • 5.1.3 Microchips
      • 5.1.3.1 Organ on a Chip
    • 5.1.4 Others
  • 5.2 By Application
    • 5.2.1 Drug Discovery
    • 5.2.2 Tissue Engineering
    • 5.2.3 Clinical Applications
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Research Laboratories and Institutes
    • 5.3.2 Biotechnology and Pharmaceutical Companies
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World (ROW)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BiomimX S.r.l.
    • 6.1.2 CN Bio Innovations
    • 6.1.3 Corning Incorporated
    • 6.1.4 Hurel Corporation
    • 6.1.5 InSphero AG
    • 6.1.6 Lonza AG
    • 6.1.7 Merck KGaA
    • 6.1.8 MIMETAS BV
    • 6.1.9 Nortis Inc.
    • 6.1.10 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS